Heron Therapeutics, Inc.

HRTX

US4277461020

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:50:26 2026-01-15 EST			5-day change	1st Jan Change
1.455 ^USD	-2.35%		+15.76%	+13.08%

01-09	Heron Therapeutics, Inc. Updates Revenue Guidance for the Fourth Quarter Ended December 31, 2025 and Full Year 2025	CI
01-09	Heron Therapeutics announces preliminary, unaudited Q4 results	RE

Heron Therapeutics announces preliminary, unaudited Q4 results

Published on 01/09/2026 at 09:43 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Heron Therapeutics, Inc.

01-09	Heron Therapeutics, Inc. Updates Revenue Guidance for the Fourth Quarter Ended December 31, 2025 and Full Year 2025	CI
01-09	Heron Therapeutics announces preliminary, unaudited Q4 results	RE
12-04	Heron Therapeutics announces inclusion of Aponvie (aprepitant)	RE
11-04	Heron Therapeutics, Inc., Q3 2025 Earnings Call, Nov 04, 2025
11-04	Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-04	Heron Therapeutics posts higher Q3 revenue, backs FY forecasts	RE
11-04	Heron Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2025	CI
25-10-28	Heron Therapeutics, Inc. Appoints Thomas Cusack to the Board of Directors and to the Nominating and Corporate Governance Committee	CI
25-09-09	Heron Therapeutics files for mixed shelf of up to $125 million - SEC filing	RE
25-08-28	Heron Therapeutics, Inc. Enters into Lease Agreement for New Corporate Headquarters	CI
25-08-15	Heron Therapeutics Adopts Rights Plan to Protect Tax Benefits	MT
25-08-12	Heron Therapeutics Insider Bought Shares Worth $2,649,819, According to a Recent SEC Filing	MT
25-08-08	Heron Therapeutics, Inc., Q2 2025 Earnings Call, Aug 08, 2025
25-08-08	Heron Therapeutics, Inc. announced that it expects to receive $62.699956 million in funding	CI
25-08-08	Heron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-08	Heron Therapeutics, Inc. Reaffirms Earnings Guidance for the First Quarter 2025	CI
25-08-08	Heron Therapeutics Completes Capital Restructuring	MT
25-08-08	Heron Therapeutics Q2 revenue rises 3.3%, raises EBITDA guidance	RE
25-08-08	Heron Therapeutics announces Q2 2025 financial results and highlights commercial progress	RE
25-06-09	HC Wainwright Initiates Coverage on Heron Therapeutics With Buy Rating, $6 Price Target	MT
25-05-06	Heron Therapeutics, Inc., Q1 2025 Earnings Call, May 06, 2025
25-05-06	Sector Update: Health Care Stocks Fall Late Afternoon	MT
25-05-06	Heron Settles Patent Litigation With Mylan Over Cinvanti, Aponvie; Shares Rise	MT
25-05-06	Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-06	Heron Therapeutics, Inc. Updates Earnings Guidance for the First Quarter 2025	CI

Chart Heron Therapeutics, Inc.

Duration

Period

HRTX: Dynamic Chart

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Employees

122

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company